The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

(2012) Alan H. B. Wu et al.   BREAST CANCER RESEARCH AND TREATMENT

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide

(2012) Jennifer Gjerde et al.   BREAST CANCER RESEARCH AND TREATMENT

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy

(2012) Solai Elango Damodaran et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers

(2012) Kerri A. Schoedel et al.   CLINICAL DRUG INVESTIGATION

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Y. Nakamura et al.   JNCI-Journal of the National Cancer Institute

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) James M. Rae et al.   JNCI-Journal of the National Cancer Institute

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Meredith M. Regan et al.   JNCI-Journal of the National Cancer Institute

Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-Genomic Signaling

(2012) Kazufumi Ohshiro et al.   PLoS One

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

(2011) Kazuma Kiyotani et al.   BREAST CANCER RESEARCH AND TREATMENT

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

(2011) Anne-Joy M. de Graan et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes

(2010) Madhu S. Singh et al.   BREAST

Orally administered Endoxifen is a new therapeutic agent for breast cancer

(2010) Ateeq Ahmad et al.   BREAST CANCER RESEARCH AND TREATMENT

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

(2010) Nava Siegelmann-Danieli et al.   BREAST CANCER RESEARCH AND TREATMENT

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

(2010) Laurent Azoulay et al.   BREAST CANCER RESEARCH AND TREATMENT

Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

(2010) A Ahmad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer

(2010) Vincent O. Dezentjé et al.   JOURNAL OF CLINICAL ONCOLOGY

Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients

(2010) Kazuma Kiyotani et al.   JOURNAL OF CLINICAL ONCOLOGY

No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications

(2009) T. P. Ahern et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry

(2009) S.F. Teunissen et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Single time point diagnostic breath tests: a review

(2009) Anil S Modak   Journal of Breath Research

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer

(2008) V. O. Dezentje et al.   CLINICAL CANCER RESEARCH

Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype

(2008) J. Steven Leeder et al.   JOURNAL OF CLINICAL PHARMACOLOGY